Vivos Expands Florida Sleep Center via SPCVA Collaboration; Target 2027 Revenue
Aug 28, 2026, 8:47 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The deal creates a near-term development milestone (Q1 2027 revenue start) and a scalable operating model, potentially expanding addressable OSA care and driver for incremental revenue/margin expansion. However, execution risks (site leasing, licensing, payer enrollment) could delay impact and limit immediate price moves, as seen with other healthcare partnerships that require multi-year ramp.
AI summary
What happened, with direct paths to the underlying reporting
Vivos Therapeutics announced definitive collaboration agreements with South Palm Cardiovascular Associates to form AIM Florida, a physician-aligned MSO, to operate a regional Sleep & Airway Medicine Center in Palm Beach County. The venture targets ~250 patients/month with up to $6 million in annual revenue and 30%+ margins, with the first treatments anticipated in Q1 2027, signaling a potential near-term revenue ramp.
Vivos signs definitive collaboration with SPCVA to establish SAMC in Palm Beach County.
AIM Florida to be 75% owned by Vivos; operations slated for Q1 2027.
Initial Sleep Optimization Team targets 250 patients per month; up to $6M revenue.
First patient treatment expected in early 2027; growth potential with add-on teams.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
